# COVID-19 vaccination: challenges in the pediatric population

## TL;DR

This paper reviews the effectiveness and safety of COVID-19 vaccines in children aged 0 to 18 years, highlighting the need for ongoing monitoring of long-term side effects.

## Contribution

The paper provides a comprehensive review of recent studies on pediatric vaccination against SARS-CoV-2, emphasizing immune response and safety.

## Key findings

- Clinical trials show a sustained immune response in children after vaccination.
- Most studies confirm the safety and effectiveness of vaccination schedules in children and adolescents.
- Long-term side effects remain to be monitored for future vaccine improvements.

## Abstract

Vaccination is considered to be one of the most effective means of protecting individuals and populations from the risks associated with exposure to various pathogens. The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), affected people of all ages worldwide. In response, several pharmaceutical companies rapidly leveraged their resources to develop vaccines within a very short period of time, leading to the introduction of new, improved, and combination vaccines for community-wide immunization. This review aims to provide a summary of the available literature on the efficacy and safety of COVID-19 vaccines in the pediatric population ranging from 0 to 18 years. An analysis of recent published studies reveals that the majority of clinical trials have reported a sustained immune response following COVID-19 vaccination in children across various age groups worldwide. The majority of the authors highlighted the effectiveness and safety of immunization schedules in children and adolescents. The population-level efficacy of this vaccination remains to be determined, provided that the benefits outweigh the potential risks. Long-term side effects must still be monitored to enable the development of safer and more effective vaccines for future pandemics.